Genetic studies lead to clinical trial of new treatment for type 1 diabetes

June 11, 2013, University of Cambridge
Credit: Heather Aitken from Flickr

(Medical Xpress)—A clinical trial is underway for a potential new treatment for type 1 diabetes that could eventually mean patients are able to reduce insulin treatment from several times a day to only once or twice a week. The new treatment is a direct result of research to understand the genetics of the disease.

Type 1 diabetes is the most common severe worldwide and the incidence of the disease is rising rapidly. It causes the to mistake cells in the as harmful and attack them. When these cells are damaged the pancreas is unable to produce insulin, which plays an essential role in transferring out of the and into cells to be converted into energy. The management of type 1 diabetes usually involves measuring the amount of glucose in the blood and injecting artificial insulin to make up for the insulin the pancreas is not producing.

Type 1 diabetes is known to be a genetically complex disease – there is no single gene that causes the disease, but rather dozens of genes that increase the risk of developing the disease. However, have identified variants of one particular gene – known as interleukin-2, or IL2 – which appears to play a prominent role. IL-2 is important in helping regulate the immune system.

Now, for the first time, researchers at Addenbrooke's Hospital and the Wellcome Trust funded Cambridge Institute for Medical Research (CIMR) at the University of Cambridge are investigating whether interleukin-2 in the form of a drug called aldesleukin (Proleukin) could be used to halt the damage to the pancreas in people with newly diagnosed type 1 diabetes and, if so, what dose of the drug is required for the best results.

Professor John Todd, FRS from the JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, University of Cambridge says: "Studying the genetics of type 1 diabetes has proved essential to help us understand what is happening in the disease at a cellular and molecular level. This type of research takes time, but we are now beginning to test its true potential for improving the lives of patients in our innovative translational medicine programme."

The clinical trial is being led by Dr Frank Waldron-Lynch from the University of Cambridge and is coordinated by the Cambridge Unit at Addenbrooke's Hospital. Dr Waldron-Lynch adds: "Type 1 diabetes is a potentially very serious disease that requires lifelong treatment and regular throughout the day. Our aim is to use aldesleukin to rebalance the immune system so that patients can significantly reduce the number of insulin injections needed to just once or twice a week by slowing the progression of the disease."

The first two participants have been enrolled onto the trial and have received treatment. At the moment, the trial is to help gauge the necessary dose in adults, beginning with very low doses; ultimately, the researchers hope to be able to use this treatment in children.

Dr Waldron-Lynch says that so far the results have been very positive, even on a very low dose, with no detectable side effects. However, they are looking to recruit more participants to the "aDaptive study of IL-2 dose on regulatory T cells in type 1 Diabetes" (DILT1D) to help them determine with confidence whether the drug is effective and at what dose.

The trial is being funded by the Wellcome Trust and JDRF, the type 1 diabetes charity, combined with funding from the National Institute of Health Research (NIHR), a UK government body that coordinates and funds research for the National Health Service.

Dr Michael Dunn, Head of Molecular and Physiological Sciences at the Wellcome Trust, says: "We have invested heavily in genetics over the past few decades to understand the biological causes of diseases. At the same time as showing us how complex diseases are, it has also provided tantalising clues as to how they may be treated. This is the first time that 'immunotherapy'– in other words, trying to rebalance the immune system – has been trialled in the UK as a way of tackling type 1 diabetes and it would not have been possible without the strong foundation of genetics and immunology research that underpins it."

Karen Addington, Chief Executive of JDRF, said: "Across the UK, hundreds of thousands of people with suffer the disruption of insulin injections several times every day. These injections interrupt their work, their play, their time with family and sometimes their sleep. We must continue to support crucial research such as this which focuses on better treatment for those living with the condition."

Professor Gillian Griffiths, FRS, Director of the CIMR at the University of Cambridge says: "I am delighted that the and Inflammation Laboratory are rolling out this important translational medicine programme based on the cutting-edge basic biomedical research which they have carried out within the Cambridge Institute for Medical Research"

Explore further: The artificial pancreas that keeps tabs on sugar

More information: www.clinical-trials-type1-diabetes.com/

Related Stories

The artificial pancreas that keeps tabs on sugar

May 16, 2013
(Medical Xpress)—Development of a sophisticated artificial pancreas holds potential to transform the lives of patients with Type 1 diabetes.

Adult stem cells could hold key to curing Type 1 diabetes

May 29, 2013
Millions of people with type 1 diabetes depend on daily insulin injections to survive. They would die without the shots because their immune system attacks the very insulin-producing cells it was designed to protect. Now, ...

Pancreas stem cell discovery may lead to new diabetes treatments

November 14, 2012
(Medical Xpress)—Stem cells in the adult pancreas have been identified that can be turned into insulin producing cells, a finding that means people with type 1 diabetes might one day be able to regenerate their own insulin-producing ...

Discovery of human genetic mutation could lead to new treatments for type 1 diabetes

March 5, 2013
In type 1 diabetes, the immune system destroys insulin-producing cells in the pancreas, but the precise cause has not been clear. A study published by Cell Press on March 5th in Cell Metabolism reveals that a single mutation ...

Does Type 2 diabetes really exist?

May 30, 2013
The term "Type 2 diabetes" is leading medical researchers astray, and resulting in sub-optimal treatment for patients, says a leading diabetes expert in a Viewpoint published in the Lancet.

Study reveals therapeutic targets to alter inflammation, type 2 diabetes

March 12, 2013
New research from Boston University School of Medicine (BUSM) reveals that B cells regulate obesity-associated inflammation and type 2 diabetes through two specific mechanisms. The study, published in the Proceedings of the ...

Recommended for you

Genetic discovery may help better identify children at risk for type 1 diabetes

January 17, 2018
Six novel chromosomal regions identified by scientists leading a large, prospective study of children at risk for type 1 diabetes will enable the discovery of more genes that cause the disease and more targets for treating ...

Women who have gestational diabetes in pregnancy are at higher risk of future health issues

January 16, 2018
Women who have gestational diabetes mellitus (GDM) during pregnancy have a higher than usual risk of developing type 2 diabetes, hypertension, and ischemic heart disease in the future, according to new research led by the ...

Diabetes gene found that causes low and high blood sugar levels in the same family

January 15, 2018
A study of families with rare blood sugar conditions has revealed a new gene thought to be critical in the regulation of insulin, the key hormone in diabetes.

Discovery could lead to new therapies for diabetics

January 12, 2018
New research by MDI Biological Laboratory scientist Sandra Rieger, Ph.D., and her team has demonstrated that an enzyme she had previously identified as playing a role in peripheral neuropathy induced by cancer chemotherapy ...

Enzyme shown to regulate inflammation and metabolism in fat tissue

January 11, 2018
The human body has two primary kinds of fat—white fat, which stores excess calories and is associated with obesity, and brown fat, which burns calories in order to produce heat and has garnered interest as a potential means ...

Big strides made in diabetes care

January 5, 2018
(HealthDay)—This past year was a busy, productive one for diabetes research and care.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.